Ambispective research about the association between adverse event and use of edaravone in patients with acute cerebral infarction.
Not Applicable
- Conditions
- Stroke
- Registration Number
- JPRN-UMIN000003938
- Lead Sponsor
- Hisayama Research Institute For Lifestyle Diseases Graduate School of Medical Sciences, Kyushu University Gunma University, School of health science
- Brief Summary
27th ICPE: International Conference on Pharmacoepidemiology & Therapeutic Risk Management (Aug 14-17, 2011)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6500
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Renal disorder within 21 days.
- Secondary Outcome Measures
Name Time Method Death within 30 days. And other adverse event, liver injury, thrombocytopenia and intracranial bleeding within 21 days